Tresiba (insulin degludec) and Lantus (insulin glargine ... of body weight daily Administer Tresiba and Lantus subcutaneously once daily at any time of day but at the same time every day.

Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia ... In particular, it will give Tresiba an edge over Lantus in a highly competitive market, where biosimilars are ...

Rapid-acting Fiasp (insulin aspart) is for patients to take at mealtime, while long-acting Tresiba (insulin deguldec) is injected daily. The price reduction for Fiasp matches the 75% cut in the U ...

Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...